US$ 29.57
glp-1 obesity drugs pipeline Transforming obesity: The advancement of multi-receptor drugs: Cell GLP-1 Pipeline graphic : r/Zepbound
Description
Exclusion criteria: Non-RCTs (cohort, casecontrol, cross-sectional studies, case reports)

For example, in the STEP 4 trial, participants who stayed on semaglutide for 68 weeks lost an additional 7.9% of their body weight

Diab 130 , 358367 (2022)

The Swedish Obesity Subjects Study from 2007 evaluated over 4,000 patients in a prospective matched control study and demonstrated improvements in mortality, mostly due to reduction in death from cancer and myocardial infarction, of up to 2030% based on the degree of obesity prior to surgery with sustained outcomes at 1015 years of follow-up [21]

Starting at the lowest dose and increasing the dose gradually over time may help to minimize side effects

Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review. Cureus , vol
